The urgency is grounded in recent experience. Uganda has faced repeated Sudan virus disease outbreaks, including the large 2022 event and a shorter 2025 outbreak that the World Health Organization declared on 30 January 2025 and ended on 26 April 2025 after 14 total cases, including 12 confirmed cases, two probable cases and four deaths. Small does not mean simple: that outbreak still spanned multiple districts, exposed health workers and required the tracing, monitoring and support of numerous contacts. Meanwhile, vaccine readiness remains uneven across Ebola viruses. The rVSV-ZEBOV vaccine, whose ring vaccination in Guinea showed substantial protection against Zaire ebolavirus, represents one of the great achievements of outbreak vaccinology. But Sudan and Bundibugyo ebolaviruses, both central to regional risk, still lack licensed vaccines, and their development pipelines have been thinner, slower and more dependent on emergency improvisation.

The authors, Ugwu Okechukwu Paul-Chima and Martin Nduwimana of Kampala International University, contend that East Africa needs a platform mindset rather than a product mindset. A product mindset waits for a specific vaccine; a platform mindset prepares the system that can update, test, produce and deliver candidates as threats change. Ebola risk is species-specific, geographically uneven and socially fast-moving. A district can move from one suspicious death to hundreds of monitored contacts within days, and if the scientific system starts only after laboratory confirmation, it is already late. The 2025 Uganda response illustrated both the danger and the opportunity: WHO and partners worked with Ugandan investigators, regulators and international filovirus experts so that candidate vaccines and treatments could be accessed once Sudan virus disease was detected, and a clinical efficacy trial for a Sudan virus vaccine was launched during the emergency, a landmark moment for Sudan virus disease vaccine evaluation. That speed deserves celebration, the authors argue, but it should also make the region restless. If so much had to be assembled under pressure, the next task is to make readiness less heroic and more ordinary, aligning with the 100 Days Mission framework and the Coalition for Epidemic Preparedness Innovations’ platform technology approach, which emphasize moving from viral detection to vaccine deployment within shorter timeframes.

The scientific case for mRNA Ebola vaccines rests on the platform’s distinctive technical features. mRNA vaccines deliver genetic instructions that allow host cells to produce a target antigen, typically through lipid nanoparticle delivery. The platform enables rapid design after sequence availability, manufacturing processes that can be standardized across targets, and the option of testing updated constructs without rebuilding the entire production chain. For Ebola disease, the glycoprotein remains the obvious starting point because it mediates viral entry and has been the central antigen for several vaccine approaches. The evidence base is early but no longer empty. Meyer and colleagues reported that lipid nanoparticle-formulated modified mRNA vaccines based on Ebola virus glycoprotein induced Ebola-specific IgG and neutralizing antibody responses and protected guinea pigs after challenge. O’Donnell and colleagues extended the RNA platform logic to Sudan virus, showing single-dose replicon RNA protection in female guinea pigs. Stromberg and colleagues reported that an mRNA vaccine expressing Ebola virus glycoprotein induced high neutralizing antibody titers and protected mice against lethal challenge. These are not field efficacy data, and the authors are careful not to oversell them, but they justify serious platform development, especially for viral species where licensed vaccines remain unavailable.

Other vaccine platforms reinforce the same point from a different angle. Vesicular stomatitis virus-based Sudan virus vaccines have protected macaques in challenge studies, and a bivalent ChAdOx1 Ebola and Sudan virus vaccination has shown early clinical safety and immunogenicity in adults. The field is clearly moving beyond Zaire-only preparedness. mRNA candidates should therefore be judged alongside these approaches on durability, T cell responses, reactogenicity, tropical stability, dosing schedule, performance in previously exposed populations and feasibility during ring vaccination. Excitement, the authors warn, is useful only if it survives field reality.

A serious argument for mRNA Ebola preparedness cannot stop at biotechnology; the region needs an ecosystem. Genomic surveillance should identify the viral species and sequence relevant targets quickly. Regional laboratories should handle sequencing data, immunological assays and quality control. Regulators should maintain pre-reviewed emergency pathways that preserve rigour without wasting time. Trial sites need trained staff, community networks, adverse event monitoring and data systems before an outbreak begins. Parts of this architecture already exist. Uganda has strong research institutions and considerable outbreak experience. The WHO mRNA technology transfer hub in South Africa was established to strengthen mRNA vaccine production capacity on the continent and support African manufacturing self-determination beyond COVID-19, offering East Africa the prospect of developing capacity in antigen design, batch release and quality assurance through partnership rather than importing finished products. Africa CDC’s Partnerships for African Vaccine Manufacturing places vaccine production within a wider continental health security agenda, while the African Medicines Agency is positioned to accelerate preparedness by developing convergent regulatory standards and pre-approved trial protocols for investigational mRNA vaccines, reducing the time and cost of bringing candidates into outbreak response trials across fragmented national jurisdictions.

Community trust is part of the platform, not a soft add-on. Ebola vaccination is a social act carried out during fear: communities may be grieving, angry or suspicious, health workers exhausted, and rumors may move faster than contact tracing teams. The term mRNA may also bring back memories of COVID-19 disputes, political messaging and online misinformation. If mRNA Ebola preparedness is built only in laboratories, it may fail at the clinic gate, the village meeting or the burial negotiation. Survivors, religious leaders, local journalists, market leaders, ambulance teams, nurses, burial teams and community health workers should be part of the conversation from the start, understanding why a Sudan virus outbreak may require a different vaccine from a Zaire virus outbreak and why trial participation can be ethical during an emergency. Religious institutions deserve particular attention: during the 2014–2016 West Africa Ebola epidemic, faith leaders were pivotal in shaping community responses to safe burial practices, quarantine compliance and rumor messaging, and their networks can amplify misinformation with the same efficiency with which they transmit reassurance. Engaging faith leaders early, before outbreaks rather than during them, is therefore a structural requirement.

Manufacturing, cold chain and delivery pose equally blunt questions. mRNA readiness will mean little if the vaccine cannot leave the capital. Ebola outbreaks may occur in rural districts, conflict-affected zones, mining corridors, crowded urban settlements or border communities where electricity, roads and internet coverage are unreliable, and some mRNA products have demanding cold chain requirements, although formulation and stability work continues to improve. Delivery models should match outbreak epidemiology: ring vaccination remains attractive because it targets contacts and contacts of contacts around confirmed cases, while health worker vaccination may be needed early because nurses, laboratory staff, ambulance teams and cleaners can become both victims and amplifiers if infection prevention fails. Supply chain fragility presents a structural obstacle: African laboratories and health facilities have long depended on imported reagents, cold chain equipment and consumables, and disruptions caused by procurement bottlenecks, shipping delays, foreign exchange shortfalls or export restrictions can halt testing and undermine biosafety. The COVID-19 pandemic exposed this dependence acutely, with diagnostic reagents becoming scarce precisely when demand was highest. Manufacturing is also political: East Africa does not need every country to build a full mRNA plant, but it does need meaningful participation in antigen selection, batch release, quality systems, pharmacovigilance, trial leadership, fill-and-finish capacity where feasible and data ownership, otherwise mRNA preparedness risks becoming another form of dependence with better branding.

Perhaps the most formidable obstacle is the way science is funded on the African continent. Readiness is a continuous state of institutional memory, trained personnel, functional infrastructure and regularly rehearsed protocols, and that continuity is extremely difficult to sustain through the dominant model of competitive international grants won institution by institution and often year by year. When a grant cycle ends, trained laboratory scientists may leave for better-paid positions, data systems may go unmaintained and community engagement networks may go dormant. The recent and severe contraction of international research funding, including cuts to United States foreign assistance and the rollback of major global health funding streams, has affected African research institutions, clinical trial networks, surveillance systems and community health programs simultaneously. The epidemiological case for a different model is clear: every gap in surveillance and every hiatus in laboratory maintenance is a gap in which an outbreak can move from a single case to a regional emergency before detection. The cost of reactive response in 2014 was estimated in the tens of billions of dollars, while the cost of sustained preparedness is a fraction of that. The authors propose treating Ebola preparedness as a recurrent line item in national health budgets, pooling contributions through East African Community and African Union frameworks, and establishing a credible business case for mRNA manufacturing by diversifying platform applications toward improved malaria vaccines, tuberculosis boosters or maternal immunization strategies, providing continuous production and stabilized revenue streams that justify capital investment.

The deeper argument is readiness. East Africa has shown that emergency vaccine trials can be activated quickly when prior planning exists, and the region should now ask what it would take to make such speed normal. That requires investment in people as much as platforms: trial nurses, laboratory scientists, data managers, regulators, logisticians, community engagement teams and manufacturing specialists, along with political seriousness, because preparedness budgets are easy to cut when there is no outbreak on the evening news. There are risks: mRNA Ebola vaccines are not yet proven field tools, preclinical protection in guinea pigs or mice does not guarantee effectiveness in humans exposed during an outbreak, and reactogenicity, dosing schedules, durability and cold chain demands could limit use. There is also a fairness risk if the technology is developed mainly through external ownership, with African sites used only when outbreaks occur. Still, the opportunity is real. Ebola preparedness has often been framed as a race against time, and mRNA platforms can help with time, but only if the region prepares the track before the race begins. The next Ebola outbreak should not find East Africa beginning again; it should find a prepared ecosystem already capable of moving from viral sequence to local readiness with speed, fairness and scientific confidence, and the financial architecture to sustain that capability between outbreaks.

Subject of Research: Virology and infectious disease

Article Title: From outbreak response to regional readiness: reimagining mRNA vaccine platforms for Ebola preparedness in East Africa

Article References: Paul-Chima, U. O., & Nduwimana, M. (2026). From outbreak response to regional readiness: reimagining mRNA vaccine platforms for Ebola preparedness in East Africa. Frontiers in Tropical Diseases, 7, Article 1887687. https://doi.org/10.3389/fitd.2026.1887687

Image Credits: AI Generated

DOI: 10.3389/fitd.2026.1887687

Keywords: mRNA vaccines, Ebola, East Africa, Sudan virus, Bundibugyo virus, outbreak preparedness, genomic surveillance, vaccine manufacturing, Africa CDC, health policy, outbreak, response

The study, led by Kevin Cissy Nabukeera, Gradi Luakanda-Ndelemo and Syrus Semawule, with joint supervision from Daudi Jjingo, Tony Wawina-Bokalanga, Placide Mbala-Kingebeni and Isaac Ssewanyana, drew on 44 Bundibugyo virus genome sequences, including 12 generated from the ongoing 2026 outbreak. The team’s central analytical target was the viral glycoprotein, the trimeric surface spike that mediates attachment and entry into host cells and that serves as the sole target of the current generation of approved and investigational ebolavirus antibody therapeutics. Because these antibodies were raised and clinically evaluated against Ebola virus, the Zaire ebolavirus species, their cross-reactivity with Bundibugyo virus cannot be assumed, and the researchers set out to map precisely where the two viruses’ glycoproteins agree and diverge at the amino acid level.

The analytical strategy combined genomic comparison with structural modelling. By aligning the Bundibugyo virus glycoprotein sequences against the Ebola virus reference and projecting the resulting substitutions onto three-dimensional models of the glycoprotein trimer, the team could identify which residues fall within the epitopes, the antibody-binding footprints, of the major therapeutic candidates. Where substitutions occurred within or adjacent to these footprints, the researchers used structural prediction tools, including resources from Google DeepMind’s AlphaFold suite, to model how the altered residues would affect the geometry, charge complementarity and binding affinity of the antibody-antigen interface. This approach allowed the team to generate predictions of therapeutic efficacy rapidly, without waiting for the slow process of isolating and testing live virus in high-containment laboratories.

The most concerning finding concerns mAb114, marketed as Ebanga, a monoclonal antibody that received regulatory approval for the treatment of Ebola virus disease following its demonstration of survival benefit in the PALM trial conducted during the 2018-2020 outbreak in the Democratic Republic of the Congo. The computational analysis revealed that two mutations in the Bundibugyo virus glycoprotein, E112D and P116A, fall within the mAb114 epitope. According to the structural models, these substitutions do not merely weaken binding; they cause the antibody to engage in off-target binding and substantially reduce its affinity for the viral surface. In practical terms, the models predict that mAb114’s efficacy against Bundibugyo virus may be compromised, a result that, if confirmed experimentally, would have immediate implications for treatment protocols in the affected region.

The picture for the second major therapeutic, the three-antibody cocktail known as Inmazeb, proved more complex and, in some respects, more encouraging. Inmazeb combines atoltivimab, maftivimab and odesivimab, three antibodies that bind distinct sites on the Ebola virus glycoprotein and were also validated in the PALM trial. The structural modelling showed that odesivimab maintains its epitope binding against the Bundibugyo virus glycoprotein, but that atoltivimab and maftivimab individually fail to bind their designated sites on the Bundibugyo virus spike. Crucially, however, when the complete trimeric cocktail was modelled against the Bundibugyo virus glycoprotein, the analysis demonstrated synergistic binding, suggesting that the cooperative action of the three antibodies together may preserve therapeutic activity even where individual components fall short.

This combinatorial effect carries a broader lesson for antiviral therapeutics. Antibody cocktails were originally designed with viral escape in mind: targeting multiple non-overlapping epitopes makes it far harder for a virus to mutate its way around the treatment. The Bundibugyo virus analysis adds a second rationale, showing that cooperation between antibodies can compensate for the loss of individual binding interactions when a therapeutic is deployed against a related but antigenically divergent virus species. The authors emphasize that the complex binding behaviour of the Inmazeb components points to the importance of antibody combinatorial effects for treatment efficacy, a consideration that should inform both the design of future pan-ebolavirus therapeutics and the interpretation of cross-species efficacy predictions.

By contrast, the analysis of the MBP134 cocktail offers the clearest cause for optimism. MBP134, a two-antibody combination developed to provide broad protection across ebolavirus species, was found to have epitopes that remain conserved in the Bundibugyo virus glycoprotein. The computational models predict that MBP134 retains its conserved targeting and holds promise as a broadly protective therapeutic against the 2026 outbreak strain. Because MBP134 was explicitly engineered to bind conserved regions of the glycoprotein across the Orthoebolavirus genus, its resilience in this analysis is consistent with its design intent, and the finding positions it as a leading candidate for experimental deployment should clinical evaluation proceed.

The authors are careful to frame their conclusions as predictions rather than proven clinical facts. Computational structural modelling, however sophisticated, cannot fully capture the dynamics of antibody-antigen interaction in biological systems, and neutralization assays performed with authentic Bundibugyo virus isolates remain the definitive test of therapeutic efficacy. The team explicitly calls for urgent experimental validation through neutralization assays, work that would require high-containment laboratory capacity and access to outbreak-derived viral stocks. The gap between computational prediction and wet-laboratory confirmation is a recurring challenge in outbreak response, and this study illustrates both the value and the limitations of moving fast with in silico evidence while definitive experiments are organized.

The collaborative structure of the research reflects the realities of modern outbreak science. The analysis brought together the African Center of Excellence in Bioinformatics and Data-Intensive Sciences at Makerere University, the Institut National de Recherche Biomédicale in Kinshasa, Uganda’s National Health Laboratory and Diagnostic Services, the Uganda Virus Research Institute, and partners including the Institute of Tropical Medicine in Antwerp, Université de Montpellier, the Pandemic Sciences Institute at Oxford, and several public health ministries and agencies across both affected countries. The work was supported in part by Google DeepMind’s AlphaFold tools and resources, a Google.org AIMaR grant, the US National Institutes of Health, the Gates Foundation and the Lacuna Fund, alongside the She Data Science programme supporting Ugandan women in health data science. This blend of African-led genomic capacity, international structural biology expertise and philanthropic and governmental funding represents a template for how future cross-border outbreak analyses can be assembled quickly.

As the 2026 Bundibugyo virus disease outbreak continues, the study’s practical message is twofold. First, treatment decisions in the field should not assume that Ebola virus therapeutics transfer automatically to Bundibugyo virus; the E112D and P116A substitutions that undermine mAb114 binding demonstrate that even single-residue changes at an epitope can reshape the therapeutic landscape. Second, genomic surveillance must be treated as a live input to therapeutic strategy, with continuous monitoring of glycoprotein sequences from new cases feeding into updated structural models and, ultimately, into neutralization testing. The rapid genomic and structural assessment published this week provides exactly that kind of early insight, and its predictions, once validated experimentally, could help determine which antibody therapies offer the best chance of saving lives in the current outbreak and in the Bundibugyo virus eruptions that will inevitably follow.

Subject of Research: Predicted efficacy of Ebola monoclonal antibody therapeutics against Bundibugyo virus in the 2026 outbreak

Article Title: Early insights into predicted efficacy of Ebola monoclonal antibodies for the 2026 Bundibugyo virus disease outbreak

Article References: Nabukeera, K. C., Luakanda-Ndelemo, G., Semawule, S., Ayitewala, A., Adroba-Tandele, P., Walakira, A., Amuri-Aziza, A., Jansen, D., Galiwango, R., Kinganda-Lusamaki, E., Tebba, A., Ngandu, C., Ssemaganda, A., Tshiani-Mbaya, O., Kanyerezi, S., Kyokushaba, J., Akil-Bandali, P., Makoha, C., Oundo, H. R., … Ssewanyana, I. (2026). Early insights into predicted efficacy of Ebola monoclonal antibodies for the 2026 Bundibugyo virus disease outbreak. Nature Communications. https://doi.org/10.1038/s41467-026-78077-9

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78077-9

Keywords: Bundibugyo virus, Ebola, monoclonal antibodies, glycoprotein, MBP134, Inmazeb, mAb114, Ebanga, structural modeling, genomic surveillance, outbreak response, neutralization assays

The timing of the announcement is not incidental. The organization arrives at a moment of mounting anxiety among epidemiologists and global health officials, as shrinking foreign aid budgets strain disease surveillance programs across the developing world and as experts warn that the conditions for another pandemic are quietly accumulating. In the months leading up to its public unveiling, Schmidt Global Health has already been operating behind the scenes, boosting public health monitoring for the 2026 World Cup, preserving an essential database of Ebola statistics, symptoms, and treatments, and supporting measles response efforts in the United States and the Pacific Islands. These early projects offer a preview of the organization’s operating philosophy: move fast, plug critical gaps, and build durable capacity rather than one-off interventions.

Wendy Schmidt, who serves as president and co-founder of the new organization, is scheduled to discuss its work at the World Health Summit in Berlin, with a livestream available to a global online audience. Her framing of the mission emphasizes the borderless nature of modern biological risk. In a statement accompanying the launch, she argued that in a world as deeply interconnected as ours, in which challenges respect no borders, solutions need to be as swift, responsive, and far-reaching as the problems themselves. She described the organization as embracing the challenge of answering an urgent international need in a rapid yet systemic way, working toward a philanthropic vision of a healthy, resilient, and secure world for all.

The technical core of Schmidt Global Health rests on four interconnected pillars of work. The first, Network, fosters collaboration across a global web of medical professionals, researchers, and public health officials, recognizing that outbreak intelligence is only as good as the human connections that carry it. The second, Information and Analysis, applies artificial intelligence, machine learning, and other computational technologies to accelerate research, analysis, and the transparent, real-time sharing of information. The third, Communication, aims to make public health news accessible and actionable for communities, addressing the well-documented failure of technical warnings to reach the people who need them most. The fourth, Emergency Response, builds resilience to prepare for and respond to public health emergencies before they cascade into catastrophes.

The application of artificial intelligence to epidemic detection is among the most consequential technical bets embedded in this strategy. Eric Schmidt, co-founder of the organization and a longtime advocate for American leadership in AI, noted that AI is already transforming the world of medicine by accelerating data collection and analysis, the discovery of treatments, and the dissemination of information and care. With Schmidt Global Health, he said, that impact can be deepened with the explicit hope of preventing the next pandemic before it starts. In practice, this means deploying machine learning models to sift through vast, noisy streams of open-source data, from clinical reports to news feeds, to surface early signals of unusual disease activity that traditional reporting systems might catch too late or miss entirely.

The organization’s grantmaking portfolio illustrates how these ambitions translate into concrete support for working public health systems. Schmidt Global Health funds the World Health Organization’s Health Emergencies Programme, which is currently scaling up support for the governments of the Democratic Republic of the Congo and Uganda in response to an active Ebola crisis, strengthening surveillance, contact tracing, clinical preparedness and management, supply delivery, community engagement, and cross-border preparedness. It also supports the WHO Hub for Pandemic and Epidemic Intelligence in Berlin, including the Epidemic Intelligence from Open Sources platform, the world’s leading initiative for open-source intelligence in public health decision-making, and the GOARN Berlin Fellowship Programme, which trains the next generation of outbreak responders.

Human capital receives particular attention across the portfolio. The WHO Berlin Hub’s Syrian Field Epidemiology Training Program supports the training of local epidemiologists in disease tracking, outbreak investigation, data analysis, rapid response, and the use of AI tools for public health, an investment in expertise within a health system devastated by more than a decade of conflict. In the United States, the organization funds the Council of State and Territorial Epidemiologists’ Applied Epidemiology Fellowship and its Leading Epidemiologists, Advancing Data Fellowship, both designed to improve coordination across public health jurisdictions for epidemiologic reporting and information sharing while preparing for global events such as the World Cup, which concentrates enormous, mobile crowds and creates distinctive surveillance challenges.

Data preservation and regional cooperation form a third strand of the work. The Sierra Leone Ebola Database, a joint project of the Sierra Leone Ministry of Health and Sanitation and the Centers for Disease Control and Prevention, preserves and manages treatment, testing, death, burial site, risk factor, and symptom data from the 2014 to 2016 West African Ebola outbreak, serving both the humanitarian purpose of helping families visit their loved ones’ resting places and the scientific purpose of providing a vital research resource for preparing for future outbreaks. In the Pacific, the organization supports the Pacific Public Health Surveillance Network, a voluntary coalition spanning 22 island countries and territories that detects and responds to emergencies including dengue fever, measles, typhoid, and cholera, with funding directed toward data collection and field epidemiology training in partnership with the Pacific Community and the Pacific Island Health Officers Association.

Communication and clinical research round out the portfolio. Schmidt Global Health supports The Conversation, a nonprofit, independent news organization that translates peer-reviewed research into accessible journalism, whose stories were read 550 million times across its global network in the past year, an acknowledgment that public understanding is itself a public health intervention. The organization also carries forward the clinical legacy of the Schmidt Initiative for Long Covid, funding scientists at Nova Southeastern University, Western University, and Scripps Research who are testing whether therapies already approved by the FDA for other conditions can provide relief from Long Covid symptoms, using AI to cross-reference drugs against the largest set of patient and proteomic data of any similar studies and conducting the first fully remote clinical trial for the condition.

John Redd, chief executive officer of Schmidt Global Health, framed the launch as a response to a structural void in the global health landscape. Philanthropy, he argued, has an opportunity to fill a gap in the public health landscape to improve pandemic detection and response, and he expressed enthusiasm for expanding the Long Covid initiative’s model to take on more public health challenges at a time of immense need worldwide. Whether a private foundation can meaningfully offset the erosion of government-funded surveillance remains an open question, but the organization’s early record, from World Cup monitoring to Ebola data preservation to Pacific measles response, suggests a strategy built on speed, technical leverage, and partnership with the professionals already doing the work. As the architects of the new nonprofit see it, the cost of the next pandemic will dwarf the cost of the systems needed to stop it, and the time to build those systems is now.

Subject of Research: A new philanthropic nonprofit strengthening global public health surveillance and pandemic response systems

Article Title: Eric and Wendy Schmidt announce global public health nonprofit to improve systems that monitor, identify, respond to health threats

Article References: Eric and Wendy Schmidt announce global public health nonprofit to improve systems that monitor, identify, respond to health threats. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Schmidt Global Health, global public health, pandemic preparedness, disease surveillance, artificial intelligence, epidemiology, World Health Organization, Ebola, Long Covid, field epidemiology training, open-source epidemic intelligence, philanthropy

The core of the concern raised by APIC and SHEA is operational rather than abstract. Infection preventionists and healthcare epidemiologists working on the front lines of American medicine depend daily on the CDC’s science, surveillance systems, and guidance documents to make decisions that protect both patients and healthcare personnel. When a hospital investigates a cluster of healthcare-associated infections, when a nursing home must respond to an outbreak of a respiratory pathogen, or when an outpatient clinic needs to update its vaccination protocols, the technical foundation for those decisions typically originates at the federal agency. According to the joint statement, that foundation is visibly weakening: guidance is slower to arrive, technical assistance is harder to reach, and scientific expertise is thinner precisely when it is most needed.

The timing of the reported workforce losses amplifies the risk. Healthcare facilities are entering the respiratory virus season without updated federal vaccine recommendations, a gap that leaves infection prevention teams without the authoritative national benchmarks they have historically relied upon to standardize immunization practices across institutions. At the same time, facilities are preparing for potential measles exposures, a disease that demands rapid identification, isolation, and contact tracing protocols grounded in current epidemiological evidence. The organizations also point to the monitoring of imported threats such as Ebola, which requires sustained laboratory capacity, surveillance infrastructure, and rapid communication channels between federal scientists and local practitioners. Each of these scenarios depends on a functioning national public health partner, and each becomes more hazardous when that partner is operating with a substantially reduced workforce.

Infection prevention is a discipline built on the rapid translation of scientific evidence into bedside practice. Infection preventionists are the specialists who design and enforce the protocols that prevent healthcare-associated infections, which affect millions of patients worldwide each year and represent one of the most common adverse events in medical care. Healthcare epidemiologists complement this work by applying epidemiological methods to detect outbreaks, evaluate antimicrobial resistance patterns, and assess the effectiveness of preventive interventions within healthcare settings. Both professions operate within a distributed network in which local expertise is amplified by national coordination. The CDC functions as the hub of that network, synthesizing data from thousands of facilities, issuing evidence-based recommendations, and providing the laboratory and technical infrastructure that individual institutions cannot replicate on their own.

APIC President Kathy Ward, a registered nurse with advanced credentials in infection control, framed the relationship between frontline practitioners and the federal agency as a partnership that is now under strain. In the statement, she emphasized that infection preventionists safeguard the nation’s healthcare system against healthcare-associated infections and that the profession depends on the CDC to provide timely, evidence-based guidance. She warned that the losses described in the reporting put that partnership, and patient safety itself, at risk. Her comments reflect a practical reality: when federal guidance is delayed or unavailable, individual facilities must improvise, and improvisation in infection control can lead to inconsistent practices, gaps in protection, and ultimately preventable infections.

SHEA President Lisa Maragakis, a physician and epidemiologist, directed her warning toward a longer-term consequence of workforce erosion. In the statement, she observed that healthcare epidemiology is built on sound science and trusted data, and she characterized the CDC’s scientific independence and expert workforce as national assets that cannot be rebuilt overnight once they are lost. This point carries particular technical weight. The scientists who staff the agency’s emerging infectious disease and respiratory disease centers accumulate institutional knowledge, methodological expertise, and operational experience that are not easily transferred or replaced. Experienced federal scientists develop the capacity to recognize early signals of emerging threats, to design surveillance systems that capture meaningful data, and to communicate complex findings to practitioners who need actionable guidance. When such experts depart, their institutional memory departs with them, and rebuilding that capacity requires years of recruitment, training, and mentorship.

The downstream effects of a weakened CDC do not remain contained within the agency. As APIC and SHEA describe it, when the national partner is weakened, the burden shifts to already stretched healthcare facilities and to state and local health departments, many of which have faced their own staffing and funding challenges in recent years. State and local public health agencies depend on federal technical assistance, laboratory confirmation capabilities, and coordinated data systems to carry out their mandates. When federal capacity contracts, these agencies absorb responsibilities they may lack the resources to fulfill, and the resulting gaps propagate outward to patients and communities, who ultimately bear the consequences in the form of increased exposure to preventable infections and slower responses to outbreaks.

In response to the situation, the two organizations have issued a three-part call to action directed at Congress and the Administration. First, they urge the restoration and sustained support of CDC staffing in infectious disease programs, healthcare quality promotion, and laboratory operations, the specific divisions whose expertise underpins infection prevention practice nationwide. Second, they call for the protection of the agency’s scientific independence, reflecting a concern that political interference in scientific processes would further undermine the credibility and reliability of federal guidance. Third, they demand that funds appropriated for state and local public health partners be distributed promptly, ensuring that the frontline agencies responsible for local outbreak response receive the resources that Congress has already allocated. Together, these recommendations address the workforce, the institutional safeguards, and the funding pipelines that the organizations view as the essential infrastructure of national infection prevention capability.

The statement also situates the current moment within a broader understanding of how healthcare safety is produced. The prevention of healthcare-associated infections is not achieved by any single institution acting alone; it is the product of a layered system in which federal science, state and local public health infrastructure, and frontline clinical expertise reinforce one another. Surveillance data collected by the CDC inform the guidelines that infection preventionists implement in their facilities, and the observations of those frontline practitioners in turn feed back into national evidence. Disruption at any layer degrades the entire system, but disruption at the federal layer is particularly consequential because it affects every facility simultaneously. The organizations’ warning suggests that the reported loss of nearly a third of the agency’s workforce represents precisely such a systemic disruption, one whose effects are already observable in delayed guidance and reduced access to technical assistance.

As respiratory virus season proceeds and as facilities continue to prepare for measles exposures and monitor imported threats, the concerns articulated by APIC and SHEA are likely to frame an ongoing policy debate about the nation’s public health readiness. The organizations’ message is that the expertise housed within the CDC constitutes a form of national infrastructure comparable in importance to physical systems, and that its loss carries consequences measured not in budget figures but in patient outcomes. Their statement serves as both a diagnosis of the current strain on the infection prevention community and a formal request to federal policymakers to restore the scientific capacity on which American healthcare safety has long depended. Whether that request translates into legislative and administrative action remains to be seen, but the two societies have made clear that, in their assessment, the window for protecting this critical national asset is narrowing.

Subject of Research: Impact of CDC workforce reductions on infection prevention and healthcare epidemiology

Article Title: APIC and SHEA Statement on reported erosion of CDC capacity

Article References: APIC and SHEA Statement on reported erosion of CDC capacity. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: CDC, APIC, SHEA, infection prevention, healthcare epidemiology, public health workforce, healthcare-associated infections, respiratory virus season, vaccine recommendations, measles, Ebola, health policy